Expert Offers Advice to Community Oncologists for Patients With Pancreatic Cancer
Hani M. Babiker, MD, shares his advice for community oncologists treating patients with pancreatic cancer.
Hani M. Babiker, MD, assistant professor and associate director of the phase I program at the University of Arizona Cancer Center, shares his advice for community oncologists treating patients with pancreatic cancer.
Babiker says the most important advice is to enroll patients in clinical trials. Enrollment is still low on a national level and pancreatic cancer is a highly lethal disease. He hopes to see more data come out from clinical trials in the field.
From an academic perspective, Babiker advises to look to the light at the end of the tunnel and to continue working towards more clinical trials. He hopes to see molecular targeting and immunotherapy play a role in the treatment of pancreatic cancer in the future, but more research is necessary.
See more from the 2019 Gastrointestinal Cancers Symposium.
Durvalumab Plus Chemo Continues to Improve Survival in Biliary Tract Cancer
April 16th 2024Results from a 3-year follow-up of the TOPAZ-1 trial showed that treatment with durvalumab plus chemotherapy in advanced biliary tract cancer continued to improve overall survival vs chemotherapy alone.
Read More
The Impact of the Gut Microbiome in Young Patients With Colorectal Cancer
February 15th 2021In season 2, episode 2 of Targeted Talks, Cathy Eng, MD, speaks with Benjamin Weinberg, MD, about the gut microbiome, and how the presence of certain microbiota impact the onset and intensity of disease as well as the potential response to certain treatments.
Listen
KEYNOTE-859 Outcomes Influence NCCN Guidelines on Pembrolizumab in Upper GI Cancer
April 10th 2024During a Case-Based Roundtable® event, David Zhen, MD, discussed how treatment of upper gastrointestinal cancer with pembrolizumab and chemotherapy is impacted by PD-L1 composite positive score, in the second article of a 2-part series.
Read More
